Ken Monteith, executive director of a network of AIDS organizations in Quebec called COCQ-SIDA, says Canada is not on track to meet global targets regarding the sexual health of people living with HIV.
Use should be restricted to clinical trials; other options are recommended for non-severe COVID-19, including nirmatrelvir–ritonavir (Paxlovid) and remdesivir.